FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Orchestra BioMed Holdings, Inc. Stock AnalysisComprehensive stock analysis for Orchestra BioMed Holdings, Inc. (OBIO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisOBIO
OBIO
Orchestra BioMed Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OBIO
Home🔹Stocks🔹Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.

OBIO•NASDAQ

Orchestra BioMed Holdings, Inc.

OBIO•NASDAQ
Market cap
$231.14M
Sentiment

Your view on OBIO

Mkt Cap
$231.14M
Sentiment
Your view
OBIO
Orchestra BioMed Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OBIO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Orchestra BioMed Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
David P. Hochman
Headquarters
150 Union Square Drive, New Hope, PA, US
Industry
Biotechnology
Sector
Healthcare
CEO
David P. Hochman
Headquarters
150 Union Square Drive, New Hope, PA, US
Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News